Disruption of SLFN11 Deficiency–Induced CCL2 Signaling and Macrophage M2 Polarization Potentiates Anti–PD-1 Therapy Efficacy in Hepatocellular Carcinoma
出版年份 2023 全文链接
标题
Disruption of SLFN11 Deficiency–Induced CCL2 Signaling and Macrophage M2 Polarization Potentiates Anti–PD-1 Therapy Efficacy in Hepatocellular Carcinoma
作者
关键词
-
出版物
GASTROENTEROLOGY
Volume 164, Issue 7, Pages 1261-1278
出版商
Elsevier BV
发表日期
2023-03-09
DOI
10.1053/j.gastro.2023.02.005
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer
- (2022) Bingnan Zhang et al. BRITISH JOURNAL OF CANCER
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors
- (2021) Ukhyun Jo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- SLFN11 inactivation induces proteotoxic stress and sensitizes cancer cells to ubiquitin activating enzyme inhibitor TAK-243
- (2021) Yasuhisa Murai et al. CANCER RESEARCH
- Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study
- (2021) Lauren Averett Byers et al. CLINICAL CANCER RESEARCH
- RBM10: Structure, functions, and associated diseases
- (2021) Akira Inoue GENE
- A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers
- (2021) Bingnan Zhang et al. BRITISH JOURNAL OF CANCER
- SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer
- (2021) Claudia Winkler et al. JCI Insight
- Prognostic Significance of SLFN11 Methylation in Plasma Cell-Free DNA in Advanced High-Grade Serous Ovarian Cancer
- (2021) Victoria Tserpeli et al. Cancers
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features
- (2020) Changyu Zhu et al. JOURNAL OF HEPATOLOGY
- Overexpression of SMAD7 activates the YAP/NOTCH cascade and promotes liver carcinogenesis in mice and humans
- (2020) Haichuan Wang et al. HEPATOLOGY
- SLFN11 can sensitize tumor cells towards IFN-γ-mediated T cell killing
- (2019) Riccardo Mezzadra et al. PLoS One
- Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade
- (2019) Ying Zhu et al. GUT
- Macrophages and hepatocellular carcinoma
- (2019) Zhiqiang Tian et al. Cell and Bioscience
- Mechanisms Controlling PD-L1 Expression in Cancer
- (2019) Jong-Ho Cha et al. MOLECULAR CELL
- Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma
- (2019) Liang-qing Dong et al. JOURNAL OF HEPATOLOGY
- Overall survival in a trial of orally administered CCR2 inhibitor CCX872 in locally advanced/metastatic pancreatic cancer: Correlation with blood monocyte counts.
- (2018) David Linehan et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
- (2018) M. Catherine Pietanza et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- SLFN11 Blocks Stressed Replication Forks Independently of ATR
- (2018) Junko Murai et al. MOLECULAR CELL
- Understanding the tumor immune microenvironment (TIME) for effective therapy
- (2018) Mikhail Binnewies et al. NATURE MEDICINE
- Targeting the IL-6/JAK/STAT3 signalling axis in cancer
- (2018) Daniel E. Johnson et al. Nature Reviews Clinical Oncology
- Low expression of WW domain-containing oxidoreductase associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection
- (2018) Chenhao Zhou et al. Cancer Medicine
- Notch Signaling in the Tumor Microenvironment
- (2018) Olivier Meurette et al. CANCER CELL
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- Integrin CD11b activation drives anti-tumor innate immunity
- (2018) Michael C. Schmid et al. Nature Communications
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin
- (2017) Jun Chen et al. NATURE
- An RRM–ZnF RNA recognition module targets RBM10 to exonic sequences to promote exon exclusion
- (2017) Katherine M. Collins et al. NUCLEIC ACIDS RESEARCH
- A Natural CCR2 Antagonist Relieves Tumor-associated Macrophage-mediated Immunosuppression to Produce a Therapeutic Effect for Liver Cancer
- (2017) Wenbo Yao et al. EBioMedicine
- Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial
- (2016) Timothy M Nywening et al. LANCET ONCOLOGY
- Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma
- (2015) Xiaoguang Li et al. GUT
- F-box protein FBXW7 inhibits cancer metastasis in a non-cell-autonomous manner
- (2015) Kanae Yumimoto et al. JOURNAL OF CLINICAL INVESTIGATION
- Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
- (2015) Nan Chen et al. Journal of Thoracic Oncology
- Advances in targeted therapies for hepatocellular carcinoma in the genomic era
- (2015) Josep M. Llovet et al. Nature Reviews Clinical Oncology
- Combination cancer immunotherapies tailored to the tumour microenvironment
- (2015) Mark J. Smyth et al. Nature Reviews Clinical Oncology
- A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors
- (2013) Shahneen K. Sandhu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells
- (2013) Martin Franz Sprinzl et al. HEPATOLOGY
- RBM5, 6, and 10 Differentially Regulate NUMB Alternative Splicing to Control Cancer Cell Proliferation
- (2013) Elias G. Bechara et al. MOLECULAR CELL
- Codon-usage-based inhibition of HIV protein synthesis by human schlafen 11
- (2012) Manqing Li et al. NATURE
- Hepatocellular Carcinoma
- (2011) Hashem B. El-Serag NEW ENGLAND JOURNAL OF MEDICINE
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- (2010) Riccardo Lencioni et al. SEMINARS IN LIVER DISEASE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started